Weight-loss drugs have been a hot topic this year. However, when asking about the developing GLP-1 market we found a divergence of views. Respondents were evenly split between seeing the market as ‘very large with long-term sustainability’, 33%, cautious on the ‘substantial risks that could deflate the market’, 35%, and of the view that information is too limited to express a clear view, 32%. In sum, while it is clear that there may be substantial upside for the GLP-1 market, uncertainties remain, further information is still needed and we need to be mindful of the risks.